Sentences with phrase «particular effects of the disease»

A new study found out that the brains of schizophrenic patients attempt to heal themselves by restructuring brain tissue damages and fighting particular effects of the disease.

Not exact matches

While the possible protective effect of smoking against PSC seems rather unique to this particular liver disease, coffee consumption has been shown to protect against multiple other liver conditions including liver cirrhosis and liver cancer — and now for the first time also against PSC.

«We are the first to publish these types of findings and, importantly it offers the opportunity to not only monitor the progress of the disease but also to determine if particular drugs / treatment are having an effect.»

The correction means that the meta - analysis now says people who report eating lots of this particular fat have significantly less heart disease; previously, it said there was no significant effect.

Researchers analyzed the raw scores and adjusted for the effects of various demographic factors, medical history, disease severity and treatments received, to isolate the particular effects of smoking.

In particular, a transgenic mouse model of early Alzheimer's disease shows that the more focally targeted an intervention is, the more specific of an effect can be elicited.

Susan Amara, USA - «Regulation of transporter function and trafficking by amphetamines, Structure - function relationships in excitatory amino acid transporters (EAATs), Modulation of dopamine transporters (DAT) by GPCRs, Genetics and functional analyses of human trace amine receptors» Tom I. Bonner, USA (Past Core Member)- Genomics, G protein coupled receptors Michel Bouvier, Canada - Molecular Pharmacology of G protein - Coupled Receptors; Molecular mechanisms controlling the selectivity and efficacy of GPCR signalling Thomas Burris, USA - Nuclear Receptor Pharmacology and Drug Discovery William A. Catterall, USA (Past Core Member)- The Molecular Basis of Electrical Excitability Steven Charlton, UK - Molecular Pharmacology and Drug Discovery Moses Chao, USA - Mechanisms of Neurotophin Receptor Signaling Mark Coles, UK - Cellular differentiation, human embryonic stem cells, stromal cells, haematopoietic stem cells, organogenesis, lymphoid microenvironments, develomental immunology Steven L. Colletti, USA Graham L Collingridge, UK Philippe Delerive, France - Metabolic Research (diabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transporters

Drug Labels FDA drug labels contain the name of the particular symptom, disease, or subset of patients within a disease that the drug is approved to treat, along with instructions for using the drug properly (including the dosage and what to do when a patient misses a dose), a description of any special instructions for taking the drug (such as with food or water), storage instructions, the symptoms of side effects to the drug, the names of any conditions or foods the patient should not have while using the medication, any warnings or precautions, any risk of drug tolerance or dependency, and a list of drug ingredients.

Phase II Trials clinical studies conducted to evaluate the effectiveness of the drug for a particular disease or signs or symptoms in patients with the disease or condition under study and to determine the common short - term side effects and risks.

The study results indicate that flavonoids, in particular a group known as anthocyanins, could have neuroprotective effects, suggesting that flavonoids could be a healthy and natural approach to reduce the risk of getting Parkinson's disease.

In particular, calorie - focused thinking is inherently biased against high - fat foods, many of which appear to be protective against obesity and the diseases of metabolic syndrome, and supportive of refined starch and sugar replacements, which are clearly detrimental, and exclusive of their calories and effects on weight gain [27], [28].

Immunity is security from a particular disease - it may develop from acquiring a disease and then recovering (kind of risky, especially if the disease is usually fatal or has severe side effects), or by being effectively immunized.

Immature heartworms can still cause damaging effects, in particular, in the form of a disease called heartworm associated respiratory disease (HARD).

Workload, in particular tight deadlines, too much work and too much pressure or responsibility, a lack of managerial support, organisational changes at work, violence and role uncertainty are identified causes of work - related stress.1 These factors are antecedents of sickness presenteeism which is mediated by mental and physical health.2 At the individual level, chronic stress produces long - term deleterious effects in health, namely, cardiovascular diseases, 3 burn - out, anxiety and depression.4 Sickness absence in Europe is associated with psychosocial work factors.5 The link between work performance, stress and health poses an important challenge to workers, employers and organisations in general, as stress should be monitored and mitigation measures implemented accordingly.6